TACT vs TECH · rev $10.2M vs P/E 65, rev $1.22B
TransAct Technologies Incorporated (TACT) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
TransAct Technologies Incorporated (TACT) is a computer hardware company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported TACT revenue for 2024-12-31 was $10.2M. Net income was -$8.0M. Revenue was down 5.9% from 2024-09-30 to 2024-12-31. TACT currently screens at market cap $49.3M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
TACT currently screens at market cap $49.3M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the TACT and TECH stock pages for the full models.
Not investment advice.